Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
In support of National Asthma and Allergy Awareness Month, Mylan goes to bat to help baseball fans with peanut allergies enjoy one of America's favorite pastimes
BASKING RIDGE, N.J., May 29, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), today announced it is partnering with an all-star roster of baseball teams to host Allergy Awareness games at select stadiums across the country. Mylan Specialty, the marketer of EpiPen® (epinephrine) Auto-Injector, will kick off the series of games with the Pittsburgh Pirates. The Allergy Awareness games will feature reserved seating areas for people with potentially life-threatening (severe) allergies to peanuts, the most common food allergen among children.
The Allergy Awareness games, kicking off during National Asthma and Allergy Awareness Month, are part of the year-long celebration recognizing the 25th anniversary of the U.S. Food and Drug Administration's (FDA) approval of the EpiPen Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of life-threatening allergic reactions (anaphylaxis). Anaphylaxis has many possible triggers, occurs quickly, without warning, and must be treated immediately with epinephrine. Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector.
"In 2012, Mylan partnered with the Pittsburgh Pirates to host the first annual Allergy Awareness game, and we are excited to expand the effort this year with events across the country," said Heather Bresch, CEO of Mylan. "We are proud to partner with these teams to help families managing severe allergies attend a baseball game for what may be their first time at the ballpark. These Allergy Awareness games are just one example of our commitment to help meet the needs of people at risk for anaphylaxis."
Avoidance of allergic triggers is the critical first step to prevent a life-threatening allergic reaction, but accidental exposure may still happen, so you should be prepared to respond if this serious health emergency occurs. People at risk for anaphylaxis should have an anaphylaxis action plan in place which includes avoiding known allergens, recognizing symptoms, having access to two EpiPen Auto-Injectors and seeking immediate emergency medical care should anaphylaxis occur.
Throughout the games, fans will have the opportunity to learn more about severe allergies. This is especially important because an estimated one in 13 children in the U.S. suffer from a food allergy. Each team will highlight severe allergy facts and figures on screens throughout the stadium, and will invite one fan who is at risk for anaphylaxis to throw out the first pitch.
Allergy Awareness Game Details:
- Pittsburgh Pirates vs. Cincinnati Reds, PNC Park, Friday, May 31, 2013 at 7:05 p.m.
"Last year's Allergy Awareness Night at PNC Park was a terrific success, so we are thrilled to partner once again with Mylan Specialty on this important initiative," said Pirates President Frank Coonelly. "We are pleased to offer our fans affected by peanut allergies more opportunities to experience Pirates baseball in a supportive environment."
For more information on anaphylaxis, severe allergies and EpiPen Auto-Injector, visit epipen.mediaroom.com.
EpiPen® (epinephrine) 0.3 mg and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen and EpiPen Jr are intended for immediate self administration as emergency supportive therapy only. Seek immediate emergency medical treatment after use.
Important Safety Information
EpiPen Auto-Injectors contain a single dose of epinephrine, which you inject into your outer thigh. DO NOT INJECT INTO YOUR VEIN, BUTTOCK, FINGERS, TOES, HANDS OR FEET. In case of accidental injection, please seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Tell your doctor if you have certain medical conditions such as asthma, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure and heart disease, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your doctor all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you take the EpiPen or EpiPen Jr Auto-Injector.
The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest.
Talk to your healthcare professional to see if EpiPen or EpiPen Jr Auto-Injector is right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Anaphylaxis is a life-threatening allergic reaction that has many possible triggers, occurs quickly, without warning, and must be treated immediately with epinephrine. Symptoms may include hives or redness of the skin, tightness in the throat, nausea, dizziness, breathing problems, a decrease in blood pressure and/or fainting. Anaphylaxis can be caused by triggers such as food, stinging and biting insects, medicines, latex or even exercise. Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Epinephrine is a naturally-occurring hormone, also known as adrenaline, and it should be available at all times to patients at risk. Delays in epinephrine administration have been associated with negative health consequences, even possibly death.
About EpiPen® Auto-Injector 25th Anniversary
Mylan Specialty L.P. is commemorating the 25th anniversary of the FDA approval of the EpiPen Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector. This year we recognize 25 years of progress and continue the momentum to increase anaphylaxis awareness, preparedness and access to treatment. In addition to our continued commitment to the advocacy community, Mylan will offer the 25th anniversary "$0 Co-Pay Offer" card to provide additional support to patients. The offer is available to both cash-paying and commercially insured patients, including those with a high deductible. Certain restrictions apply. Patients can contact Mylan Customer Service at 1-800-796-9526 to obtain a coupon and can obtain additional information about the co-pay card at www.EpiPen.com. Mylan is also continuing to offer the EpiPen4Schools™ program, which offers four free EpiPen or EpiPen Jr Auto-Injectors, upon qualification, which includes having a valid prescription, to public and private kindergarten, elementary, middle and high schools in the U.S. For complete program details, visit www.EpiPen4Schools.com.
About EpiPen® Auto-Injector
EpiPen® and EpiPen Jr® Auto-Injectors are used for the emergency treatment of life-threatening allergic reactions. Each EpiPen 2-Pak® and EpiPen Jr 2-Pak® contains two single auto-injectors, instructions for use and a training device, with no drug product or needle, to help patients become familiar with the administration technique. EpiPen Auto-Injector should be administered immediately at the first sign of an anaphylactic reaction. EpiPen Auto-Injector is not a substitute for emergency medical treatment. Patients should seek emergency medical attention immediately following administration. For more information about EpiPen Auto-Injector, please visit www.EpiPen.com.
About Mylan Specialty
Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. For more information, please visit www.mylanspecialty.com.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
EpiPen®, EpiPen Jr®, EpiPen 2-Pak® and EpiPen Jr 2-Pak® are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P.
EpiPen4Schools™ is a trademark of Mylan Specialty L.P.
© 2013 Mylan Specialty L.P. All rights reserved.
SOURCE Mylan Inc.
More by this Source
Mylan Launches First Generic ORTHO EVRA® Patch
Apr 16, 2014, 16:13 ET
Mylan Announces Settlement Agreement for First-to-File Generess® Fe
Apr 15, 2014, 10:20 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.